|
|
|
Volumn , Issue 110, 2007, Pages 1-8
|
|
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIRETROVIRUS AGENT;
CHEMOKINE RECEPTOR CCR5;
CHEMOKINE RECEPTOR CXCR4;
CYCLOHEXANE DERIVATIVE;
HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;
TRIAZOLE DERIVATIVE;
ADULT;
ANTIVIRAL RESISTANCE;
ARTICLE;
BLOOD;
CANADA;
CD4 LYMPHOCYTE COUNT;
DRUG APPROVAL;
DRUG EFFECT;
ECONOMICS;
EUROPE;
GENETICS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LEGAL ASPECT;
LYMPHOCYTE;
PLANT GROWTH;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
UNITED STATES;
VIROLOGY;
VIRUS LOAD;
ADULT;
ANTI-HIV AGENTS;
ANTI-RETROVIRAL AGENTS;
CANADA;
CD4 LYMPHOCYTE COUNT;
CYCLOHEXANES;
DRUG APPROVAL;
DRUG RESISTANCE, VIRAL;
EUROPE;
HIV FUSION INHIBITORS;
HIV INFECTIONS;
HIV-1;
HUMANS;
LYMPHOCYTES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECEPTORS, CCR5;
RECEPTORS, CXCR4;
TREATMENT OUTCOME;
TRIAZOLES;
TROPISM;
UNITED STATES;
VIRAL LOAD;
|
|
EID: 38449111432
PISSN: 14886324
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
